Product Images Venlafaxine Hydrochloride

This text appears to be a list of interacting drugs and their effects on analytes like venlafaxine, along with recommendations for PK Fold Change and 90% CI. The list also includes advice on avoiding concomitant use or using with caution in certain patients.*

This is a drug interaction table showing the effects of various drugs on each other when taken concomitantly. The table lists drugs such as ethanol, diazepam, alprazolam, indinavir, metoprolol, and lithium, among others, and the recommended dose adjustments, if any. The table lists fold changes in PK (pharmacokinetics) and 90% CI (confidence interval). Additionally, the table mentions drugs that should be used with caution, and some should be avoided if possible.*

This is a chart or table indicating recommendations for dosage adjustments for the drug venlafaxine based on specific patient populations, including those with hepatic impairment (cirrhosis, mild or moderate impairment), renal impairment (hemodialysis), CYP2D6 polymorphism, age (>60 years), and gender. The chart suggests reductions in dose for most of the patient populations mentioned, with some recommendations for individualization of dosing. The chart also includes information on changes in PK (pharmacokinetics) and fold change relative to reference values.*

This is a medication description for Venlafaxine HCL 75mg extended-release capsules manufactured by Annora Pharma Pvt. Ltd. They are pink and white in color and may cause drowsiness. The capsules should be stored at room temperature and kept away from children. The package contains 90 capsules and has an expiration date of MM/YY. The NDC number for this medication is 7133518681 03325901523487. The rest of the text appears to be a label from a supplier or distributor and is not relevant to the medication description.*